Zometa was designed as an osteoporosis drug, and the exclusive rights to manufacture it was almost over – the patent was expiring.
Zometa is expensive for the patient, and profitable for the manufacturer; keeping the patent active for another 3 years by extending the approved use would create a highly profitable marketing miracle for the manufacturer.
With sales of $1.26 billion for osteoporosis treatment, Novartis tried to expand the use of Zometa as an breast-cancer drug.
But it didn’t work the way they wanted. This article suggests that Zometa makes breast cancer worse.
What about those women with both osteoporosis and breast-cancer? Especially those whose breast cancer was not yet discovered at the time they began to take Zometa.
Zometa is similar to other drugs for other conditions: they all cause the body to respond to the drug in an isolated fashion, and the body may push-back or respond or compensate in an unexpected fashion that can make the body worse than it was without the drug.
Natural methods that encourage the body to battle these problems do not cause this type of problem. Do your own research to find the natural tools around you that support your own natural healing processes of your own body, and trust your body to do what only it can do.
This from FiercePharma, an online newsletter for the pharmaceutical industry:
Generic: Zoledronic Acid
Company: Novartis ($NVS)
Patent expiration date: March 2, 2013
Estimated Global Sales 2012: $1.26 billion
The scoop: Zometa continues to sell in excess of $1 billion annually, and Novartis has been trying a number of strategies to fend off generic attacks on the bone-strengthening medication for cancer patients. It applied in the U.S. and Europe for a new indication to treat breast cancer, which if approved would have added three additional years of exclusivity.
But Novartis dumped that effort in 2010 when a study showed that the drug not only didn’t keep breast cancer at bay or prolong patients’ lives, it had almost exactly the opposite effects.
The same year it came to an understanding with Teva Pharmaceutical Industries ($TEVA) over the U.S. launch of a generic, with Teva agreeing to hold off until the 2013 patent expiration. European regulators have cleared Mylan ($MYL) and Teva to market copies of Zometa there, and another generics maker is making a run at the drug in the U.S. In July, Novartis sued India’s Sun Pharmaceutical Industries over its application to produce copies of Zometa and Novartis’ Reclast, for post-menopausal osteoporosis, which also goes off patent next year.
Below is a list of osteoporosis drugs, common drug treatment for osteoporosis. These drugs do not prevent osteoporosis, they interfere with the normal bone rebuilding process – in my opinion are not a safe or effective treatment for osteoporosis.
According to information from the FDA released March 2008, there are warnings in affect for all bisphosphonate drugs commonly used for osteoporosis treatment: Fosamax, Fosamax Plus D, Didronel, Boniva, Aredia, Actonel, Actonel W/Calcium, Skelid, Reclast, Zometa.
Bisphosphonates are risky and can be dangerous, and there is no guarantee these treatments can help improve your bone density dexa scores. There are better, more natural osteoporosis treatments available that make a real difference in your bone density and bone strength. You can learn more right here at Bone Density Blog, and at Bone Density Secrets.
Dr. Martin McIntosh
* These names are registered trademarks of the manufacturers. Alendronate (Fosamax, Fosamax Plus D®), Etidronate (Didronel®), Ibandronate (Boniva®), Pamidronate (Aredia®), Risedronate (Actonel®, Actonel W/Calcium®), Tiludronate (Skelid®), Zoledronic acid (Reclast, Zometa®)